Skip to content

KIORA PHARMACEUTICALS, INC.: 10-Q filed 2017-08-04

What KIORA PHARMACEUTICALS, INC. reported in its quarterly report filed 2017-08-04 (fiscal Q2 2017): 30 published measures, 79 facts as tagged in accession 0001144204-17-040582.

This filing

Form
10-Q (quarterly report)
Filed
2017-08-04
Fiscal period
fiscal Q2 2017
Accession
0001144204-17-040582 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All KIORA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-06-3018,313,431USD
At 2016-12-319,730,602USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-06-3013,744,406USD
At 2016-12-3110,060,023USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-06-304,569,025USD
At 2016-12-31-329,421USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-06-3011,763,137USD
At 2016-12-313,635,224USD
At 2016-06-308,026,419USD
At 2015-12-318,394,133USD

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-06-30-84,845,255USD
At 2016-12-31-78,598,738USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-06-3028,967USD
At 2016-12-3138,040USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-06-30512,141USD181
2016-01-01 to 2016-06-30237,404USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-3,326,794USD91
2017-01-01 to 2017-06-30-6,246,406USD181
2016-04-01 to 2016-06-30-3,826,089USD91
2016-01-01 to 2016-06-30-6,268,839USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-06-3012,446,482USD
At 2016-12-314,154,038USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-04-01 to 2017-06-30305USD91
2017-01-01 to 2017-06-30608USD181
2016-04-01 to 2016-06-300USD91
2016-01-01 to 2016-06-300USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-06-3010,998,764USD
At 2016-12-317,308,058USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-06-30970,912USD
At 2016-12-311,412,128USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-04-01 to 2017-06-303,475,084USD91
2017-01-01 to 2017-06-306,579,228USD181
2016-04-01 to 2016-06-304,060,689USD91
2016-01-01 to 2016-06-306,503,439USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-04-01 to 2017-06-302,262,193USD91
2017-01-01 to 2017-06-304,077,193USD181
2016-04-01 to 2016-06-302,481,534USD91
2016-01-01 to 2016-06-303,395,506USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-06-3017,204,778shares
At 2016-12-3110,130,883shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2017-06-3089,177,942USD
At 2016-12-3178,106,645USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-06-30123,108USD
At 2016-12-31120,187USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2017-06-304,569,025USD
At 2016-12-31-329,421USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2017-06-3013,609USD
At 2016-12-314,536USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-06-30354,772USD
At 2016-12-3155,314USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2017-06-301,166,452USD
At 2016-12-311,670,930USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-06-30519,559USD
At 2016-12-31464,981USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-3,326,863USD91
2017-01-01 to 2017-06-30-6,246,517USD181
2016-04-01 to 2016-06-30-3,823,281USD91
2016-01-01 to 2016-06-30-6,265,714USD182

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2017-01-01 to 2017-06-30-6,246,517USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-301,212,891USD91
2017-01-01 to 2017-06-302,502,035USD181
2016-04-01 to 2016-06-301,579,155USD91
2016-01-01 to 2016-06-303,107,933USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-04-01 to 2017-06-304,536USD91
2017-01-01 to 2017-06-309,072USD181
2016-04-01 to 2016-06-30161USD91
2016-01-01 to 2016-06-30245USD182

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2017-01-01 to 2017-06-309,072USD181
2016-01-01 to 2016-06-30245USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-69USD91
2017-01-01 to 2017-06-30-111USD181
2016-04-01 to 2016-06-302,808USD91
2016-01-01 to 2016-06-303,125USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2017-01-01 to 2017-06-3011,922,252USD181
2017-06-01 to 2017-06-148,800,000USD14
2017-02-01 to 2017-02-211,800,000USD21
2016-01-01 to 2016-06-303,768,750USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-06-30-441,216USD181
2016-01-01 to 2016-06-30533,766USD182

Inspect the source

Entity
KIORA PHARMACEUTICALS, INC. / CIK 0001372514
Captured
2026-09-20T07:57:09.611Z
SEC response SHA-256
3c8ad9197d1b760a7f418642919ba51ce1343d392d1a4d1fce0d72996117d019

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001372514.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))